Top

Published in:

01-06-2018 | Original Article

Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants

Authors: Alimohammad Fatemi, Azadeh Ghanbarian, Zahra Sayedbonakdar, Mehdi Kazemi, Abbas Smiley

Published in: Clinical Rheumatology | Issue 6/2018

Abstract

The aim of this study was to determine the prevalence of metabolic syndrome (MetS) in Iranian patients with systemic lupus erythematosus (SLE) and its determinants. In a cross-sectional study, 98 patients with SLE and 95 controls were enrolled. Prevalence of MetS was determined based on American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) and 2009 harmonizing criteria. In addition, demographic features and lupus characteristics such as disease duration, pharmacological treatment, laboratory data, SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage index (SDI) were recorded. The predictors of MetS were obtained by backward stepwise regression analysis. Using AHA/NHLBI, MetS was observed in 35 (35.7%) patients and 28 (29.8%) controls (P = 0.4). Using harmonizing criteria, MetS was observed in 37 (37.7%) patients and 33 (35.1%) controls (P = 0.7). There was no difference in frequency distribution of MetS components between the patients and the controls. In multivariate regression analysis, low C3, blood urea nitrogen (BUN), and body mass index were independent determinants of MetS in lupus patients. BUN, low C3, and body mass index were the major determinants of MetS in lupus patients.

O'Sullivan M, Bruce IN, Symmons DP (2016) Cardiovascular risk and its modification in patients with connective tissue diseases. Best Pract Res Clin Rheumatol 30(1):81–94. https://doi.org/10.1016/j.berh.2016.03.003 CrossRefPubMed

Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G (2003) Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum 48(11):3159–3167. https://doi.org/10.1002/art.11296 CrossRefPubMed

Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A (2004) Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 43(7):924–929. https://doi.org/10.1093/rheumatology/keh213 CrossRef

Bruce IN (2005) 'Not only...But also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44(12):1492–1502. https://doi.org/10.1093/rheumatology/kei142 CrossRef

Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44(10):2331–2337. https://doi.org/10.1002/1529-0131(200110)44:10%3C2331::AID-ART395%3E3.0.CO;2-I CrossRefPubMed

McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28(2):385–390. https://doi.org/10.2337/diacare.28.2.385 CrossRefPubMed

Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110(10):1245–1250. https://doi.org/10.1161/01.cir.0000140677.20606.0e CrossRefPubMed

Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49(4):403–414. https://doi.org/10.1016/j.jacc.2006.09.032 CrossRefPubMed

Parker B, Bruce IN (2010) The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin N Am 36:81–97, viii. https://doi.org/10.1016/j.rdc.2009.12.004 CrossRef

10.

Parker B, Bruce I (2013) SLE and metabolic syndrome. Lupus 22(12):1259–1266. https://doi.org/10.1177/0961203313502570 CrossRefPubMed

11.

Azimi-Nezhad M, Herbeth B, Siest G, Dade S, Ndiaye NC, Esmaily H, Hosseini SJ, Ghayour-Mobarhan M, Visvikis-Siest S (2012) High prevalence of metabolic syndrome in Iran in comparison with France: what are the components that explain this? Metab Syndr Relat Disord 10(3):181–188. https://doi.org/10.1089/met.2011.0097 CrossRefPubMed

12.

Noshad S, Abbasi M, Etemad K, Meysamie A, Afarideh M, Khajeh E, Asgari F, Mousavizadeh M, Rafei A, Neishaboury M, Ghajar A, Nakhjavani M, Koohpayehzadeh J, Esteghamati A (2017) Prevalence of metabolic syndrome in Iran: a 2011 update. J Diabetes 9(5):518–525. https://doi.org/10.1111/1753-0407.12438 CrossRefPubMed

13.

Tabatabaie AH, Shafiekhani M, Nasihatkon AA, Rastani IH, Tabatabaie M, Borzoo AR, Hojat F (2015) Prevalence of metabolic syndrome in adult population in shiraz, southern Iran. Diabetes Metab Syndr 9(3):153–156. https://doi.org/10.1016/j.dsx.2015.04.012 CrossRefPubMed

14.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y CrossRefPubMed

15.

Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed

16.

Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363–369. https://doi.org/10.1002/art.1780390303 CrossRefPubMed

17.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112(17):2735–2752. https://doi.org/10.1161/circulationaha.105.169404 CrossRefPubMed

18.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645. https://doi.org/10.1161/circulationaha.109.192644 CrossRefPubMed

19.

Parker B, Ahmad Y, Shelmerdine J, Edlin H, Yates AP, Teh LS, Bruce IN (2011) An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 20(14):1459–1465. https://doi.org/10.1177/0961203311416695 CrossRefPubMed

20.

Sabio JM, Zamora-Pasadas M, Jimenez-Jaimez J, Albadalejo F, Vargas-Hitos J, Rodriguez del Aguila MD, Hidalgo-Tenorio C, Gonzalez-Gay MA, Jimenez-Alonso J (2008) Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 17(9):849–859. https://doi.org/10.1177/0961203308093554 CrossRefPubMed

21.

El Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM, Durrington PN, Laing I, Bruce IN (2006) Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 33(1):50–56PubMed

22.

Vadacca M, Margiotta D, Rigon A, Cacciapaglia F, Coppolino G, Amoroso A, Afeltra A (2009) Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 36(2):295–297. https://doi.org/10.3899/jrheum.080503 CrossRefPubMed

23.

Azevedo GD, Gadelha RG, Vilar MJ (2007) Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA. Ann Rheum Dis 66(11):1542. https://doi.org/10.1136/ard.2007.074583 CrossRefPubMedPubMedCentral

24.

Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R, Berman H, Santana M, Molina MJ, Gongora V, Cassano G, Paira S, Saurit V, Retamozo S, Alvarellos A, Caerio F, Alba P, Gotero M, Velozo EJ, Ceballos F, Soriano E, Catoggio L, Garcia MA, Eimon A, Aguero S (2009) Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 18(11):1019–1025. https://doi.org/10.1177/0961203309105876 CrossRefPubMed

25.

Negron AM, Molina MJ, Mayor AM, Rodriguez VE, Vila LM (2008) Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 17(4):348–354. https://doi.org/10.1177/0961203307086645 CrossRefPubMedPubMedCentral

26.

Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Stein CM (2007) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66(2):208–214. https://doi.org/10.1136/ard.2006.054973 CrossRefPubMed

27.

Zabetian A, Hadaegh F, Azizi F (2007) Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract 77(2):251–257. https://doi.org/10.1016/j.diabres.2006.12.001 CrossRefPubMed

28.

Hwang LC, Bai CH, Chen CJ (2006) Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 105(8):626–635. https://doi.org/10.1016/s0929-6646(09)60161-3 CrossRefPubMed

29.

Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S (2007) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 49(21):2112–2119. https://doi.org/10.1016/j.jacc.2007.01.088 CrossRefPubMed

30.

Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE (2007) The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 77(3):471–478. https://doi.org/10.1016/j.diabres.2007.02.002 CrossRefPubMed

31.

Ford ES, Giles WH (2003) A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26(3):575–581. https://doi.org/10.2337/diacare.26.3.575 CrossRefPubMed

32.

Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, Olaiz G, Rull JA, Sepulveda J (2004) High prevalence of metabolic syndrome in Mexico. Arch Med Res 35(1):76–81. https://doi.org/10.1016/j.arcmed.2003.06.006 CrossRefPubMed

33.

Hatef-Fard MR, Khodabandeh M, Sahebari M, Ghayour-Mobarhan M, Rezaieyazdi Z (2016) Metabolic syndrome in lupus patients in northeast of Iran, and their lifestyle habits. Caspian J Intern Med 7(3):195–200PubMedPubMedCentral

34.

Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, Mediavilla JD, Navarrete N, Ramirez A, Hidalgo-Tenorio C, Jaimez L, Martin J, Jimenez-Alonso J (2009) Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36(10):2204–2211. https://doi.org/10.3899/jrheum.081253 CrossRefPubMed

35.

Liu SY, Han LS, Guo JY, Zheng ZH, Li H, Zhang L, Zhang X, He YJ, Gao GM, Liu ZS, Zeng XF (2013) Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. Lupus 22(5):519–526. https://doi.org/10.1177/0961203313478301 CrossRefPubMed

36.

Bultink IE, Turkstra F, Diamant M, Dijkmans BA, Voskuyl AE (2008) Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 26(1):32–38PubMed

Title: Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants
Authors: Alimohammad Fatemi
Azadeh Ghanbarian
Zahra Sayedbonakdar
Mehdi Kazemi
Abbas Smiley
Publication date: 01-06-2018
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 6/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3970-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Aortic, carotid intima-media thickness and flow- mediated dilation as markers of early atherosclerosis in a cohort of pediatric patients with rheumatic diseases

Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis

Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch–Schonlein purpura in children

The association between osteoarthritis and sleep duration in Koreans: a nationwide cross-sectional observational study

Autoimmune/inflammatory syndrome induced by mineral oil: a health problem

Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page